Market Overview

UPDATE: Canaccord Genuity Raises PT to $71 on BioMarin Pharmaceutical on Upcoming Catalysts

Related BMRN
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
BioMarin to Acquire Rights to Phenylketonuria Franchise From Merck Serono for Upfront Payment of €340M, Plus Milestones
Tarix Orphan's TXA127 Fast Track'd for DMD (Seeking Alpha)

Canaccord Genuity maintained BioMarin Pharmaceutical (NASDAQ: BMRN) with a Buy rating and raised the price target from $56.00 to $71.00.

Canaccord Genuity commented, "Given that we view 2013 as a key value inflection point for BMRN's pipeline and did not previously include 5 of the 6 drugs (excludes Vimizim) in our valuation, we conducted physician diligence to analyze each clinical program – resulting in positive feedback and representing additional peak worldwide revenue of $1.7B. We are optimistic on upcoming catalysts: P1/2 BMN-701 data (Pompe) in late March (though we assume a 15% probability of success on conservatism given the high bar); BMN-673 data (cancer) at ASCO (May 31-June 4); clinical progress of PEG-PAL for PKU (P3 initiation in Q2); BMN-111 for achondroplasia (P2 initiation in mid-'13); and BMN-190 for Batten (IND filing in H1)."

BioMarin Pharmaceutical closed at $54.84 on Monday.

Latest Ratings for BMRN

Oct 2015Raymond JamesInitiates Coverage onOutperform
Aug 2015JefferiesMaintainsBuy
Aug 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (BMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters